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ABSTRACT
We evaluated the interaction between oncolytic, replication-competent
adenoviral vectors and the herpes simplex virus-1 thymidine kinase
(HSV1-tk) gene/ganciclovir (GCV) suicide system for the treatment of
malignant gliomas. We constructed a panel of replication-competent ad-
enoviral vectors in which the luciferase (IG.Ad5E1. E3Luc) or HSV1-tk
gene (IG.Ad5E1.E3TK) replace the Mr 19,000 glycoprotein (gp19K) cod-
ing sequence in the E3 region. IG.Ad5E1. IG.Ad5.ClipLuc and IG.AdA-
pt.TK are E1-deleted viruses that contain the luciferase or the HSV1-tk
gene in the former E1 region driven by the human cytomegalovirus
promoter. IG.Ad5.Sarcoma 1800HSA.E3Luc contains an irrelevant
gene in the E1 region, whereas the gp19K coding sequence in the E3
region is replaced by the luciferase gene as in the replicating virus
IG.Ad5E1.E3Luc. For in vitro experiments, we used a panel of human
glioma cell lines (U87 MG, T98G, A172, LW5, and U251), a rat gliosar-
coma cell line (9 L), and human lung (A549) and prostate carcinoma (P3)
cell lines. In vitro, GCV sensitivity (10 g/ml) was studied in U87 MG cells
after infection at a multiplicity of infection of 1 and 10. A s.c. U87 MG
glioma xenograft model was established in NIH-bg-nu-xid mice. Tumors
of 100–150 mm3 were treated with a single injection of adenovirus 109 IU
suspended in 100 l of PBS, and GCV 100 mg/kg was administered i.p.
twice daily for 7 days. The cytopathic effect of all three replication-
competent adenoviral vectors was similar to the cytopathic effect of
wild-type adenovirus 5 on all human cell lines tested, indicating that
deletion of the E3 gp19K sequences did not affect the oncolytic effect of the
vectors. In vitro, luciferase expression was the same for both E1-deleted
vectors (IG.Ad5.ClipLuc and IG.Ad5.Sarcoma 1800HSA.E3Luc), demon-
strating the strength of the internal E3 promoter even in the absence of
E1A. However, in vitro expression levels obtained with replication-
competent IG.Ad5E1. E3Luc were 3 log higher (allowing infection
with a 2–3-log lower multiplicity of infection) in the human cell lines. In
U87 MG glioma cells, the oncolytic effect of replication-competent
IG.Ad5E1.E3TK was significantly enhanced by the addition of GCV and
greatly exceeded the cytotoxicity of replication-incompetent IG.AdApt.TK
combined with GCV. In established s.c. U87 MG glioma xenografts, a
single injection of IG.Ad5E1.E3TK resulted in a significant slowing of
tumor growth and prolonged survival compared with injection of
IG.AdApt.TK. Addition of GCV slowed tumor growth, further adding to
survival. In conclusion, the oncolytic effect of replicating adenoviral vec-
tors and HSV1-tk/GCV have potent antitumor effects in gliomas. When
combined, these two approaches are complementary, resulting in a
significantly improved treatment outcome. In addition, replication-
competent adenoviral vectors missing the E3 gp19K coding sequences,
have oncolytic efficacy comparable with wild type. In combination with
high expression levels obtained with the natural E3 promoter, such vectors
are promising new anticancer agents.
INTRODUCTION
The incidence of primary brain tumors in the Western world is
9–10/100,000 persons and 7/100,000 die of brain tumors each year (1,
2). In children, brain tumors constitute a quarter of all cancer deaths,
second only after leukemia (3). In adults, malignant gliomas are the
most common primary brain tumors, and despite advances in neuro-
surgical techniques, radiation treatment, and chemotherapy, the prog-
nosis of these tumors remains dismal, with a median survival of 1
year; and 5% survive for 5 years or more (4–6). Limitations of
surgery, radiotherapy, and chemotherapy make the development of
new treatment strategies necessary (7). Despite the fact that individual
tumor cells spread through the brain at great distances from the
primary site (8, 9), 80% of malignant gliomas recur within a 2-cm
margin of the contrast-enhancing rim on computed tomography (10,
11). This high rate of local recurrence within the region of the original
tumor, combined with the very low incidence of distant metastases,
warrants the additional pursuit of locoregional treatment strategies
including gene therapy.
Gene therapy for brain tumors has demonstrated efficacy in a
variety of animal models using many different vector systems, includ-
ing retrovirus (12), adenovirus (13) adeno-associated virus (14), her-
pes virus (15), and reovirus vectors (16).
Despite promising results in experimental studies, clinical gene
therapy trials in brain tumor patients have generally been disappoint-
ing. A Phase III study of adjuvant gene therapy in 248 patients with
glioblastoma multiforme could not demonstrate any benefit of the
injection of HSV-tk3 retrovirus vector-producing cells (17). A much
smaller, Phase I, study of adeno.tk injection into malignant gliomas
demonstrated that the approach was safe but not very effective (18).
A small, uncontrolled trial of HSV-tk gene therapy in malignant
gliomas demonstrated better efficiency of replication-deficient adeno-
virus vector compared with a retrovirus vector (19).
Better efficacy is crucial for adenoviral cancer gene therapy to
become clinically relevant. Most of the adenoviruses used in the
clinical studies thus far carry a deletion in the E1 region which renders
the virus replication defective or helper-dependent. The efficacy of
adenoviral vectors could be greatly increased by using replication-
competent vectors (20). The theoretical advantages for the use of
replication-competent recombinant adenovirus vector are: (a) the cy-
tolytic effect on infected cells; (b) the subsequent spread of virus to
neighboring cells, resulting in additional tumor/tissue penetration; (c)
an enhanced immune response; and (d) higher levels of expression of
the therapeutic gene are achieved as a result of the replication of
adenovirus DNA.
For safety reasons, all replication competent adenoviral vectors are
conditionally replicating, usually by small deletions in the E1A or E1B
gene. These modifications may, however, decrease efficiency of viral
replication, whereas, in the past, intratumoral injection of wild-type
adenoviruses has not led to unwanted effects (21). To enhance further
the tumoricidal effect of the replication-competent vectors and to
provide a “fail-safe” in case of replication outside the tumor, we left
E1 intact and placed the HSV1-tk suicide gene in E3 under control of
the natural E3 promoter. We then examined the antitumor efficacy of
Received 4/16/01; accepted 10/16/01.
The costs of publication of this article were defrayed in part by the payment of page
charges. This article must therefore be hereby marked advertisement in accordance with
18 U.S.C. Section 1734 solely to indicate this fact.
1 Supported in part by European Union Biomed Grant PL96-1436.
2 To whom requests for reprints should be addressed, at Department of Neuro-
oncology, Daniel den Hoed Cancer Center, University Hospital Rotterdam, P. O. Box
5201, 3008 AE Rotterdam, the Netherlands. E-mail: sillevis@neuh.azr.nl.
3 The abbreviations used are: HSV-tk, herpes simplex virus thymidine kinase; GCV,
ganciclovir; gp19K, Mr 19,000 glycoprotein; CMV, cytomegalovirus; HSA, heat-stable
antigen; IU, infectious unit(s); m.o.i., multiplicity(ies) of infection: CPE, cytopathic
effect; wtAd5, wild-type adenovirus 5; ITR, inverted terminal repeat; Nucl., nucleotide.
8743
the nonconditional replication-competent adenoviral vectors in a
panel of glioma cell lines and in an animal model. We could demon-
strate a direct lytic effect of the vectors in human cell lines and in vivo
that was enhanced further by the suicide HSV1-tk/GCVsystem.
MATERIALS AND METHODS
Cell Lines
The human glioma cell lines U87 MG, T98G, and A172 were obtained from
the American Type Culture Collection (Manassas, VA). The LW5 and U251
human glioma cell lines were obtained from Dr. Langeveld (Department of
Pharmacology, Free University Hospital Amsterdam, Amsterdam, the Nether-
lands; Ref. 13). The 9L-rat gliosarcoma brain tumor was a gift from Dr. Hebeda
(Department of Experimental Neurosurgery, Free University Hospital Amsterdam;
Ref. 13). The A549 human lung carcinoma cell line was purchased from
Biowhittaker (Brussels, Belgium; Ref. 13). PC3, a human prostate cell line
(22), and human embryonic kidney 293 cells (HEK-293) were purchased from
the American Type Culture Collection. All cell lines were grown in DMEM
(Life Technologies, Inc., Breda, the Netherlands) containing 10% fetal bovine
serum (Life Technologies, Inc.), 100 units/ml penicillin, and 100 g/ml
streptomycin (Life Technologies, Inc.) and cultured at 37°C in a 5%-CO2
atmosphere.
Virus Constructions
Fig. 1 shows the structure of the different viruses used in this study.
Nonconditional Replicating Viruses. IG.Ad5E1. E3Luc and IG.Ad5E1.-
E3TK are replication-competent Ad5-based viruses in which the luciferase gene
and the HSV1-tk gene, respectively, replace the gp19K coding sequence in the E3
region. IG.Ad5E1. E3 is a replicating vector in which the gp19K gene in the E3
region is deleted. Coding sequences of the adenovirus death protein (E3–11.6K)
were not disrupted (data not shown). The IG.Ad5E1.E3TK vector was generated
as follows: a 2.7 kb EcoRI fragment from wtAd5 containing the 5 part of the E3
region was cloned into the EcoRI site of pBluescript (KS; Stratagene). Next, the
HindIII site in the polylinker was removed by digestion with EcoRV and HincII
and subsequent religation. The resulting clone, pBS.Eco-Eco/ad5HIII, was used
to delete the gp19K coding region. Primers 1 (5-GGG TAT TAG GCC AA AGG
CGC A-3) and 2 (5-GAT CCC ATG GAA GCT TGG GTG GCG ACC CCA
GCG-3) were used to amplify a sequence from pBS.Eco-Eco/ad5HIII corre-
sponding to sequences 28511–28734 in wtAd5 DNA. Primers 3 (5-GAT CCC
ATG GGG ATC CTT TAC TAA GTT ACA AAG CTA-3) and 4 (5-GTC
GCT GTA GTT GGA CTG G-3) were used on the same DNA to amplify Ad5
sequences from 29217 to 29476. The two resulting PCR fragments were
ligated together by virtue of the new introduced NcoI site and subsequently
digested with XbaI and MunI. This fragment was then ligated into the pB-
S.Eco-Eco/ad5HIII vector that was digested with XbaI (partially) and MunI-
generating pBS.Eco-Eco/ad5HIII.gp19K. To allow insertion of foreign
genes into the HindIII and BamHI site, an XbaI deletion was made in
pBS.Eco-Eco/ad5HIII.gp19K to remove the BamHI site in the pBS
polylinker. The resulting plasmid pBS.Eco-Eco/ad5HIIIgp19KXbaI, con-
tains unique HindIII and BamHI sites corresponding to sequences 28733
(HindIII) and 29218 (BamHI) in Ad5. The HSV1-TK gene was then introduced
as a HindIII-BamHI fragment into these sites, generating pBS.Eco-Eco/
Ad5.HindIII.gp19K.Xba.TK. After digestion of this construct with MunI
and HindIII, the TK-containing fragment was then introduced into pBS.Eco-
Eco/ad5HIII.gp19K, generating pBS.Eco-Eco/Ad5.HindIIIgp19k/TK.
The unique SrfI and NotI sites in this plasmid were used to transfer the region
comprising the TK gene into the corresponding region of pBr/Ad.Bam-rITRsp,
yielding construct pBr/Ad.Bam-rITR.gpTKsp. pBr/Ad.Bam-rITRsp is a
pBr322-based vector containing adenoviral sequences from Ad nucl.21562
(BamHI site) to the end of the right ITR, the latter being flanked by a unique
PacI site. The last step entailed the subcloning of the SpeI-PacI fragment from
pBr/Ad.Bam-rITR.gpTKsp into the cosmid vector pWE.Ad5.AflII-rITRsp.
pWE.Ad5.AflII-rITRsp is an pWE15- (CLONTECH) based cosmid clone
containing Ad nucl.3534 to the right ITR flanked by PacI sites. The final
construct, pWE.Ad5.AflII-rITRgpTKsp, was made by ligating the PacI-
digested cosmid backbone with a PacI-SpeI fragment corresponding to the Ad
nucl.3534–27082 from pWE.Ad5.AflII-rITRsp and the SpeI-PacI fragment
from pBr/Ad.Bam-rITR.gpTKsp. The ligation mixture was packaged in
-phage packaging extracts (Stratagene) according to the manufacturer’s pro-
tocol and introduced into DH5 cells to isolate cosmid DNA.
To generate the IG.AdE1.E3TK virus, one additional construct was made
that contains the 5 end of the Ad5, including the E1 region. Construct
pBr.AdLITR-Sal(9.4) is a pBR322-based construct that contains adenovirus
sequences from nucl. 1 to 9462 (SalI site). Transfection of pBr.AdLITR-
Sal(9.4) digested with SalI and pWE.Ad5.AflII-rITRgpTKsp digested with
PacI into PER.C6 packaging cells generates viruses through recombination of
the overlapping sequences in both constructs.
E1-deleted Viruses. IG.Ad5.ClipLuc and IG.AdApt.TK are E1-deleted
Ad5-based viruses containing the luciferase or the HSV-1 TK gene, respec-
tively, driven by the human CMV promoter in the former E1 region. The CMV
promoter in IG.AdApt.TK spans nt 735 to nt 95 (numbering according to
Ref. 23), whereas in IG.Ad5.ClipLuc, a shorter version of the CMV promoter
is present (nt 601 to nt 14). Furthermore, IG.AdApt.TK lacks the SV40
intron sequences that are present in IG.Ad5.ClipLuc. Both expression cassettes
are terminated by the SV40 polyadenylation sequence.
IG.Ad5.Sarcoma 1800HSA.E3Luc contains the mouse HSA gene (24)
driven by a Molony murine leukemia virus long terminal repeat fragment
(including the retroviral splice donor and splice acceptor site) in the former E1
region. In addition, the gp19K coding sequence in the E3 region is replaced by
the luciferase gene as in the replicating virus IG.Ad5E1.E3Luc.
All viruses were produced on PER.C6 cells (25). After one round of plaque
purification, viruses were amplified further on PER.C6 cells. Cells and viruses
were harvested 2–3 days after the final amplification in triple-layer flasks, and
Fig. 1. Scheme of nonconditional, replication-
competent adenoviral vectors and replication-incompe-
tent control adenoviral vectors.
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viral particles were purified by a two-step CsCl gradient. Virus particles in
purified virus batches were determined by high-performance liquid chroma-
tography (26), and IU were determined by end-point titration on 911 cells (27).
Virus particles:IU ratios were in all cases 30. m.o.i. is expressed as IU/cell.
In Vitro Replication
To assess replication, we determined the CPE in cultured cell lines after
infection with the various vectors. Cells were plated in 6-well plates at a
density of 105 cells/well. Twenty-four h after plating, the cells were infected
with the vectors at m.o.i. of 0, 1, or 10. The number of days from infection to
full CPE or 100% cell death was scored. As positive controls for replication,
we used the constitutively Ad5 E1-expressing cell line 293 (28) and wtAd5.
The nonpermissive rat gliosarcoma cell line 9L was used as negative control.
All experiments were performed in triplicate.
In a separate experiment, we tested the potential of HSV1-tk in combination
with GCV as a “fail-safe” for adenoviral replication. A549 cells were seeded
in 24-well plates at a density of 105 cells/well. Twenty-four h after plating, the
cells were incubated with IG.Ad5E1.E3TK or IG.Ad5E1. E3 for 2 h at
m.o.i. of 0, 0.1, or 1. Cells were treated immediately with GCV (Roche,
Mijdrecht, Netherlands) or PBS. The medium was refreshed every day, and
GCV was kept at a concentration of 10 g/ml. CPE was scored daily, and
cell viability was assessed quantitatively at days 3, 6, and 8 using the
XTT-assay following the manufacturer’s instructions (Sigma Chemical
Co., St. Louis, MO).
In Vitro Luciferase Expression
Cells were plated in 6-well plates at a density of 105 cells/well. After 24 h,
the cells were infected with the vectors at a m.o.i. of 0, 0.01, 0.05, 0.1, 0.5, 1,
5, 10, 50, or 100. Forty-eight h after infection, the cells were harvested using
Trypsin-EDTA (Life Technologies, Inc.). The cells were washed twice with
PBS (Life Technologies, Inc.). After the last wash, the cells were resuspended
in 100 l Reporter lysis buffer (Promega, Madison, WI). After centrifugation
at 14,000 rpm for 5 min, the luciferase activity was measured in the superna-
tant. The protein content of the supernatant was measured, and the luciferase
activity was expressed as relative light units/g of protein. All experiments
were performed in triplicate.
In Vitro GCV Sensitivity
U87 MG cells were plated in 6-well plates at a density of 105 cells/well.
After 24 h, the cells were infected with the replication-competent and -incom-
petent vectors carrying the HSV1-tk transgene at m.o.i. of 1 and 10. Forty-eight
h after infection, the cells were treated with GCV (Roche) or PBS for 7 days.
Day 0 is the start of treatment with GCV or PBS. The medium was refreshed
every day, and GCV was kept at a concentration of 10 g/ml. At days 1–6, the
living cells were counted using trypan blue exclusion (29). To calculate the
percentage of living cells, we divided the number of cells in the experimental
wells by the number of cells in the control wells (no vector, no GCV;100%).
All experiments were performed in triplicate.
Animal Experiments
All experimental protocols were approved by the Institutional Animal Care and
Use Committee, in compliance with the Guide for the Care and Use of Laboratory
Animals, University Hospital and Erasmus University Rotterdam, The Nether-
lands. Female Hsd:NIH-bg-nu-xid mice 5–6 weeks of age were purchased (Ref.
30; Harlan Sprague Dawley, Inc., Oxon, England). Mice were hosted 3–4/cage
and allowed access to food and water ad libitum. After 1 week, 107 U87 MG cells
were inoculated s.c. into both flanks in 500 l of HBSS (Life Technologies, Inc.).
The tumor growth was assessed by measuring bidimensional diameters three times
a week with calipers. The tumor volume was determined by using the simplified
formula of a rotational ellipse (l  width2  0.5; Ref. 31). When the tumor
reached a volume of 100–150 mm3, animals were randomly assigned to treatment
groups. Animals were treated with a single intratumoral injection of adenovirus
109 IU suspended in 100 l of PBS or 100 l of PBS alone as a control. GCV 100
mg/kg (or PBS) was administered i.p. twice daily for 7 days beginning 48 h after
vector inoculation. The animals were killed by isoflurane when their tumors
reached a volume of4000 mm2 or after 60 days. Each treatment group consisted
of a minimum of three animals (six tumors).
Statistical Analysis
Data were analyzed using GraphPad Prism version 3.0 software (GraphPad
Software, Inc., San Diego, CA, 1999). The CPE induced by replication-
competent IG.Ad5E1. E3Luc and IG.Ad5E1.E3TK and wtAd5 in the hu-
man cell lines were compared and analyzed by repeated-measures ANOVA,
and posttest analysis was performed using Dunn’s multiple comparison test.
The various treatment strategies testing in vitro U87 MG survival were
compared side by side and analyzed for significance on days 2 and 6 by
Student’s t test. Statistical significance of various vector and treatment com-
binations in vivo were analyzed by Student’s t test for normally distributed
values and by nonparametric Mann-Whitney test in the case of non-normal
distribution. All tests were performed two-sided, and P  0.05 was considered
statistically significant.
RESULTS
Replication of E1 Adenoviral Vectors. Full CPE was scored on
a variety of cell lines (Table 1). Application of all vectors containing
the wild-type E1 sequences resulted in full CPE at m.o.i. of 1 and 10.
This indicates that deletion of the gpigK coding sequences in the E3
region had not affected the oncolytic effect of the vectors. As ex-
pected, no CPE occurred on the nonpermissive rat gliosarcoma 9L cell
line. On 293 cells, all vectors, replication competent and deficient,
gave full CPE within 2 days after infection. The efficacy of replication
of the E1-containing vectors is similar to wtAd5, as measured by the
time after infection to full CPE at m.o.i. 1 (ANOVA; P 	 0.19) and
m.o.i. 10 (ANOVA; P 	 0.49). The duration to full CPE seems to be
dose dependent (ANOVA; P  0.002). In the posttest analysis, only
infection with IG.Ad5E1. E3Luc resulted in significantly shorter
time to CPE at m.o.i. 10 than at m.o.i. 1 (P  0.05). The shorter time
to CPE after infection with IG.Ad5E1.E3TK and wtAd5 at m.o.i. 10
versus 1 did not reach statistical significance (P  0.05). The time to
full CPE differed largely between cell lines. This may indicate more
efficient infection or replication in certain cell lines.
In the fail-safe experiment, the A549 cells that were treated with
GCV, immediately after infection with IG.Ad5E1.E3TK remained
96 (m.o.i., 0.1) to 98% (m.o.i., 1) viable whereas the cells treated with
PBS were only 10 (m.o.i ,1; full CPE) to 38% (partial CPE) viable at
day 8 (Fig. 2). The A549 cells infected with the replicating empty
control vector IG.Ad5E1. E3 had significantly reduced viability at
day 8 (full CPE at m.o.i. 1 and partial CPE at m.o.i. 0.1) irrespective
Table 1 Cytopathogenic effect of replication-competent adenoviral vectors
Cytopathogenic effect of replication-competent adenoviral vectors (IG.Ad5E1.-
E3Luc and IGAd5E1.E3TK) is compared with wtAd5 and nonreplicating E1-deleted
adenoviral vectors (IG.Ad5.S1800HAS.E3Luc and IGAdApt.TK) on human glioma cells
(U87MG, T98G, A172, and LW5), human lung carcinoma cells (A549), human prostate
cancer cells (PC3), and a rat glioma cell line (9L). The cells were infected with the
adenoviral vectors at a m.o.i. of 10 or 1. The days from infection to full CPE are
scored.  indicates that no full CPE was reached at the end of the experiment, 14 days
after infection. Time to full CPE is comparable between wild-type and replication-
competent adenoviral vectors. As expected, no CPE occurred on the nonpermissive rat 9L
glioma cell line. On the constitutively E1-expressing 293 cell line, all vectors, including
the E1-deleted vectors, reached full CPE.
U87MG T98G A172 LW5 A549 PC3 293 9L
m.o.i. 	 10
IG.Ad5E1.E3Luc 7 10 3 6 3 5 2 
IGAd5E1.E3TK 6 10 4 7 3 7 2 
wtAd5 6 10 4 7 3 5 2 
IG.Ad5.S1800HAS.E3Luc       2 
IGAdApt.TK       2 
m.o.i. 	 1
IG.Ad5E1.E3Luc 8 11 4 10 6 6 2 
IGAd5E1.E3TK 7 11 6 10 4 8 2 
wtAd5 7 11 4 7 4 6 2 
IG.Ad5.S1800HAS.E3Luc       2 
IGAdApt.TK       2 
8745
REPLICATING ADENOVIRUS CONTAINING HSV1-tk FOR GLIOMAS
of treatment with GCV; Fig. 2). These results show that GCV can
inhibit the replication and subsequent spread of IG.Ad5E1.E3TK,
and that the inhibition of adenoviral replication by GCV is HSV1-tk-
dependent.
In Vitro Luciferase Expression. Luciferase expression using the
E1.E3luc replication-competent vector was compared with two non-
replicating vectors containing the luciferase transgene in either E1
(driven by a modified CMV-promoter) or in E3 (driven by the E3
promoter, as in the replication-competent vector). The two nonrepli-
cating vectors gave similar luciferase expression levels in most cell
lines, indicating that the internal E3-promoter is of comparable
strength with the modified CMV-promoter (Fig. 3). However, at the
same m.o.i., the replication-competent vector yielded luciferase ex-
pression levels that were 3 log higher than with both nonreplicating
vectors in all human glioma cell lines tested (U87 MG, T98G, A172,
and LW5). Alternatively, to obtain a similar expression level, 2–3 log
Fig. 2. Replication of adenovirus vectors con-
taining the HSV1-tk gene is effectively blocked by
GCV. A549 cells were infected at a m.o.i. of 0.1
and 1 with the replication-competent vectors
IG.Ad5E1.E3TK or IG.Ad5E1. The cells in-
fected with IG.Ad5E1.E3TK and immediately
treated with GCV remain almost 100% viable.
Cells transfected with IG.Ad5E1.E3TK and sub-
sequently treated with PBS and the cells infected
with IG.Ad5E1 (and then either GCV or PBS) are
significantly less viable.
Fig. 3. Forty-eight h after infection, the luciferase expression was measured in the human glioma cell lines U87 MG, T98G, LW5, and A172; the human lung cancer cell line A549;
and the nonpermissive rat glioma cell line 9L. Expression levels with the replication-competent vector IG.Ad5E1. E3Luc are in the permissive cell lines 3 log higher than with the
replication-incompetent vectors. The expression levels obtained with nonreplicating IG.Ad5.ClipLuc (luciferase in E1 driven by a modified CMV promoter) and IG.Ad5.Sarcoma
1800HSA.E3Luc (luciferase in E3 driven by the internal E3 promoter) are comparable with each other in most cell lines. , IG.Ad5.ClipLuc; p, IG.Ad5.S1800HSA.E3Luc; f,
IG.AdE1.E3Luc.
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less IU of the replication-competent versus the nonreplicating vectors
could be used. The A549 cell line showed the same pattern as the
human glioma cell line. In the nonpermissive rat 9L cell line, expres-
sion levels with the replication-competent vector were 1 log higher
than with the nonreplicating vectors, indicating that some low-level
replication may occur.
In Vitro GCV Sensitivity of U87 MG Cells. Results of GCV
sensitivity of U87 MG cells, after infection with m.o.i. 10 and 1, are
summarized in Fig. 4. The addition of GCV at a concentration of 10
g/ml in the absence of adenoviral vectors was not cytotoxic to U87
MG cells (data not shown). Infection with nonreplicating control
vector IG.AdApt.TK and then the addition of PBS caused no signif-
icant cytotoxicity on days 2–6 at both m.o.i. (P  0.1). However,
infection with replication-competent IG.Ad5E1.E3TK and then PBS
resulted in a significant reduction of the percentage of surviving cells
compared with IG.AdApt.TK at day 6 [m.o.i. of 1, P	 0.04 (Fig. 4A);
m.o.i. of 10, P  0.0001 (Fig. 4B)]. Addition of GCV further in-
creased the cytotoxicity of IG.Ad5E1.E3TK. After infection with
IG.Ad5E1.E3TK at a m.o.i. of 1, the percentage of surviving cells
subsequent to GCV treatment was significantly lower than after PBS,
on both day 2 (P 	 0.0002) and day 6 (P  0.0001; Fig. 4A). After
infection with the replicating vector at m.o.i. 10, the number of
surviving cells was significantly lower with GCV than with PBS on
day 2 (P 	 0.004), whereas no surviving cells remained on day 6 in
both groups (Fig. 4B).
We then compared the percentage of surviving cells after infection
with either the replication-incompetent or replicating HSV1-tk-
containing vectors in combination with GCV administration. After
infection with m.o.i. 1, the percentage of surviving cells was signif-
icantly lower with the replication-competent IG.Ad5E1.E3TK com-
pared with the nonreplicating vector at both day 2 (P 	 0.04) and day
6 (P	 0.0002; Fig. 4A). After infection with m.o.i. 10, the percentage
of surviving cells was already low in both groups at day 2 (P 	 0.3),
and at day 6, no cells had survived either treatment (Fig. 4B).
In Vivo Treatment of U87 MG Xenografts in bg-nu-xid Mice.
Treatment results of s.c. U87 MG xenografts in bg-nu-xid mice are
summarized in Fig. 5 and Table 2, A–C. The growth curve of tumors
treated with PBS and then i.p. PBS was identical to the growth curve
of tumors treated with IG.AdApt.TK and then PBS. Compared with
these control curves, the intratumoral injection of replication-competent
IG.Ad5E1.E3TK gave slowing of tumor growth, resulting in signifi-
cantly reduced tumor size at days 6, 11, 18, and 27 (Table 2A and Fig. 5).
The oncolytic effect of IG.Ad5E1.E3TK was strongly enhanced by the
administration of GCV, resulting in additional slowing of tumor growth
and smaller tumor size at days 6, 11, 18, and 27 (Table 2B and Fig. 5).
Compared with the combination treatment of IG.AdApt.TK and then
GCV, replication-competent IG.Ad5E1.E3TK and then GCV was sig-
nificantly more effective (Table 2C and Fig. 5).
Survival curves demonstrate prolonged survival of mice treated
with IG.Ad5E1.E3TK in combination with GCV (Fig. 6).
DISCUSSION
To improve the efficacy of E1-deleted adenoviral vectors, we
constructed several replication-competent adenoviral vectors carrying
both E1A and E1B sequences and the HSV1-tk suicide gene. The
HSV1-tk and luciferase genes replaced the coding sequence of the E3
region gp19K that binds to class I MHC in the endoplasmic reticulum,
preventing antigen presentation on the cell surface (32). The trans-
genes were placed under control of the natural E3 promoter, because
Fig. 5. Growth of U87 MG glioma xenografts in nude mice. U87 MG cells (107) were
inoculated s.c. into both flanks in 500 l of HBSS. When the tumor reached a volume of
100–150 mm3, animals were treated with a single intratumoral injection with 109 IU of
replication-competent IG.Ad5E1.E3TK, 109 IU of nonreplicating IG.AdApt.TK, or
PBS. GCV (or PBS) was administered i.p. twice daily for 7 days (days 2–9). No difference
was observed in tumor growth in animals treated with PBS/PBS IG.AdApt.TK/PBS;
addition of GCV to animals treated with IG.Ad5E1.E3TK resulted in a significant
slowing of tumor growth; addition of GCV to animals treated with IG.AdApt.TK also
resulted in a slowing of tumor growth, although to a lesser extent than the combined
treatment with replication-competent IG.Ad5E1.E3TK and GCV. OfO, PBS/PBS;
OO, IG.AdApt.TK/PBS;OFO, IG.Ad5E1.E3TK/PBS;OŒO, PBS/GCV;OO,
IG.AdApt.TK/GCV; OO, IG.Ad5E1.E3TK/GCV.
Fig. 4. In vitro GCV sensitivity of U87 MG glioma cells. Forty-eight h after infection
with m.o.i. of 1 (A) or 10 (B), cells were exposed to PBS or GCV (10 g/ml). Surviving
cells were counted on days 2 and 6 using trypan blue exclusion and expressed as a
percentage of cells in the control wells. Compared with controls, infection with replica-
tion-competent vector expressing the HSV1-tk gene (IG.Ad5E1.E3TK) is more toxic
than the nonreplicating vector expressing HSV1-tk (IG.AdApt.TK) in combination
with PBS. The addition of GCV significantly increases the cytotoxicity of both
IG.Ad5E1.E3TK and IG.AdApt.TK. At the lower m.o.i., IG.Ad5E1.E3TK in combi-
nation with GCV is more toxic than IG.AdApt.TK. At m.o.i.	 10, both vectors are highly
effective, killing almost all cells. , no vector/PBS; z, IG.AdApt.TK/PBS; `, IG.AdA-
pt.TK/GCV; o, IG.AD5E1.E3TK/PBS; p, IG.AD5E1.E3TK/GCV.
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heterologous promoters were found to be silent when inserted in this
area (33–35). To examine the transgene expression levels obtained
from the internal E3 promoter, we also constructed an E1-deleted
vector carrying the luciferase gene in E3. The luciferase expression
obtained with this construct was similar to a first-generation, E1-
deleted vector carrying the luciferase gene in E1 driven by a modified
CMV-promoter, indicating the strength of the natural E3 promoter in
these constructs, even in the absence of E1.
Another concern was the potential disruption of the adenovirus
death protein (E3–11.6K) by our cloning strategy. Adenovirus death
protein is produced in large amounts at the late stage of infection and
is required for effective cell lysis and virus release (36). However, the
oncolytic effect of the gp19K-deleted, replicating vectors was similar
to wtAd5, as measured by the time after infection to full CPE. The
time to full CPE with both wtAd5 and the replication-competent
vectors differed largely between the tested cell lines. The time to CPE
seemed not to correlate with the level of luciferase expression, indi-
cating that the efficacy of replication may not only depend on the
efficacy of cell entry. Elucidating mechanisms affecting the efficiency
of adenoviral replication in different cell lines requires additional
study to enhance replication potentially (37). As expected, the repli-
cation-competent vectors and wtAd5 did not cause CPE in the non-
permissive 9L rat gliosarcoma cell line.
We then compared the luciferase expression levels of the E1
luciferase vector with both E1-deleted vectors and found that lucifer-
ase expression was 3 logs higher with the E1 vector in all
permissive (human) cell lines tested. Similar expression levels were
obtained with 2 log lower m.o.i. of the E1 vector. Interestingly,
infection of the nonpermissive 9L cell line with the E1 vector
resulted in significantly higher luciferase expression than with the
E1-deleted vectors. This may indicate either low-level replication of
the E1 vector in the rodent cell line or transactivation of the E3
promoter by E1 proteins.
Apart from the direct oncolytic effect on tumor cells (38), replica-
tion-competent vectors may enhance further the antitumor efficacy by
increased expression levels of a tumoricidal transgene. To test this
hypothesis, we examined the antitumor efficacy of E1 and E1-
deleted vectors carrying the HSV1-tk suicide gene. In vitro, the E1
HSV1-tk vector demonstrated cytotoxicity to the U87 MG glioma cell
line that was greatly enhanced by the addition of GCV. The latter
combination was also significantly more toxic than infection with the
E1-deleted HSV1-tk control vector and then GCV. In vivo, a single
injection of the replicative E1 HSV1-tk vector in established s.c.
U87 MG xenografts resulted in a significant slowing of tumor growth.
The addition of GCV resulted in additional slowing of tumor growth
and significantly prolonged survival. Also, the E1 HSV1-tk vector
in combination with GCV was significantly more effective than the
E1-deleted HSV1-tk vector with GCV.
Replication-competent adenoviral vectors are a new and rapidly
evolving platform for gene therapy (39). In the past, intratumoral
injection of wild-type adenoviruses has not led to unwanted effects
(21). However, “virotherapy” for cancer was abandoned because of
only a few documented responses and because of the advent of more
effective chemotherapeutic agents (20). Bischoff et al. (38) reintro-
duced the oncolytic effect of adenoviruses with vectors carrying
mutations in the early region of the encoding E1B-Mr 55,000. These
vectors only replicate in cells with a deficient p53 pathway and cause
specific cytolysis after intratumoral and i.v. administration (40). Sub-
sequently, an additive effect of HSV1-tk/GCV and radiotherapy to the
oncolytic effect of E1B-deleted vectors was demonstrated (41, 42).
The use of conditional replicating vectors that contain deletions in
E1B (or E1A) carries the risk of reduced replication as compared with
wtAd5. The present study demonstrates that even vectors replicating
as well as wtAd5 don’t cause tumor eradication in some models.
Therefore, addition of a therapeutic transgene is probably mandatory,
and genes with improved bystander and cytotoxic effects may add
Fig. 6. Kaplan-Meier survival analysis of nude mice with s.c. U87 MG xenografts. To
establish s.c. tumors, mice were inoculated s.c. in both flanks with U87 MG cells (107) in
500 l of HBSS. The tumor growth was assessed by measuring bidimensional diameters,
and when the tumor reached a volume of 100–150 mm3, animals were assigned randomly
to a single intratumoral injection with 109 IU of replication-competent IG.Ad5E1.E3TK,
109 IU of nonreplicating IG.AdApt.TK, or PBS. GCV 100 mg/kg (or PBS) was admin-
istered i.p. twice daily for 7 days beginning 48 h after vector inoculation. The animals
were killed by isoflurane when the tumors reached a volume of 4000 mm2 or after 60
days. Animals treated with replication-competent IG.Ad5E1.E3TK and GCV lived
significantly longer than animals treated with IG.Ad5E1.E3TK alone or with nonrepli-
cating IG.AdApt.TK combined with GCV.
Table 2 U87MG xenograft tumor growth after adenoviral vector treatment
Nude mice carrying s.c. U87MG glioma xenografts were treated with a single injection
of 109 IU adenoviral vector or PBS and then by either GCV or PBS (days 2–9).
Administration of replication-competent IG.Ad5E1.E3TK and then PBS results in
significant reduction in tumor growth, indicating a direct oncolytic effect of the vector
(A). Administration of GCV significantly enhances the growth suppression by the repli-
cation-competent vector (B). The replication-competent vector is more effective than the
nonreplicating vector in combination with GCV. Tumor volumes (mm3) are expressed as
mean 
 SE, and each treatment group was composed of at least six tumors.
A. Replication-competent IG.Ad5E1.E3TK and then PBS versus control
Day PBS/PBS IG.Ad5E1.E3TK/PBS P
1 85.3 
 10.2 85.3 
 10.2 1.0
6 198.3 
 51.3 381.9 
 160.0 0.3
11 381.6 
 69.2 204.2 
 28.7 0.04
18 723.8 
 130.0 403.1 
 71.1 0.05
27 4299 
 635.0 2495 
 517.4 0.05
B. Replication-competent IG.Ad5E1.E3TK and then PBS or GCV
Day IG.Ad5E1.E3TK/PBS IG.Ad5E1.E3TK/GCV P
1 85.3 
 10.2 62.5 
 0.6 0.2
6 381.9 
 160.0 12.8 
 4.9 0.002
11 204.2 
 28.7 1.3 
 0.8 0.002
18 403.1 
 71.1 0.03 
 0.02 0.002
27 2495 
 517.4 124.7 
 77.7 0.002
C. Replication-competent IG.Ad5E1.E3TK versus nonreplicating
IG.AdApt.TK and then GCV
Day IG.AdApt.TK/GCV IG.Ad5E1.E3TK/GCV P
1 85.4 
 12.7 62.5 
 0.6 0.2
6 217.0 
 61.1 12.8 
 4.9 0.002
11 223.0 
 78.2 1.3 
 0.8 0.002
18 345.7 
 181.9 0.03 
 0.02 0.002
27 855.3 
 385.7 124.7 
 77.7 0.06
31 2547 
 689.1 614.2 
 314.9 0.06
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further to the efficacy of replicating vectors (43). The toxic genes,
such as the HSV1-tk gene, can also function as a fail-safe mechanism
when replication outside the tumor occurs (41). Here, we demon-
strated that adenoviral replication and subsequent spread can be
effectively blocked by the immediate administration of GCV. The
complex interactions between viral replication and GCV require ad-
ditional in vivo studies to determine the optimal interval between
vector injection and first GCV administration. In clinical studies,
conditional replication will be required for patient- and biosafety. An
alternative for selective replication is to drive the E1B or/and E1A
genes by a tissue or tumor-specific promoter. Such vectors may
replicate in target tissue (and tumor) even better than wtAd5. Exam-
ples include the use of enhancer/promoter sequences of the prostate
specific antigen gene to drive E1A in prostate cancer (44), the -
fetoprotein promoter in hepatocellular carcinoma (45), and the DF3/
MUC1 promoter in breast cancer (46).
In the present study, we have demonstrated that the addition of the
HSV1-tk/GCV suicide system enhances the tumoricidal efficacy of
replication competent adenoviral vectors in glioma cell lines and after
intratumoral injection in a glioma xenograft model. The use of a
suicide gene has the additional advantage of fail-safe in case of spread
of the vector outside the tumor. Safety will be increased further by
conditional replication, for instance by using a glia-specific promoter
such as the gfa2 promoter, to drive the E1A gene (47).
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